Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974907 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
A Phase 3 study, sponsored by ReGenTree.
- Completed
- Registry status
- Phase 3
- Development phase
- 601
- Enrollment target
NCT02974907: Completed Phase 3 study, sponsored by ReGenTree.
NCT02974907 is a Phase 3 study that has completed, run by ReGenTree. The registered enrollment target is 601 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02974907, a Phase 3 study, has completed, sponsored by ReGenTree.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 601 participants
- Enrollment target
Study Summary
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
Primary Outcome
Change from Baseline at Day 29 using the Ora Calibra® Ocular Discomfort Scale (6-point scale where 0 = none and 5 = worst)
Interventions
- DRUG Placebo
- DRUG RGN-259
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 601 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-03 |
| Phase | Phase 3 |
What the finished NCT02974907 record still lists
NCT02974907 is an interventional study that assigns participants to a tested intervention. The registered 601 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02974907 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02974907 about?
NCT02974907 is a clinical study titled "Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2". The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
What is the current status of trial NCT02974907?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 601 participants. The study started on 2016-11. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02974907?
The interventions under investigation include: Placebo (DRUG), RGN-259 (DRUG).
Who is sponsoring clinical trial NCT02974907?
This trial is sponsored by ReGenTree, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02974907's enrollment target sits among peer trials
601 608th of 2000 higher than 1,393 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia